Using venom from the Conus nux, a sea snail, a first-of-its-kind study suggests these conotoxins could potentially treat malaria. The study provides important leads toward the development of new and cost-effective anti-adhesion or blockade-therapy drugs aimed at counteracting the pathology of severe malaria. Similarly, mitigation of emerging diseases like COVID-19 also could benefit from conotoxins as potential inhibitors of protein-protein interactions as treatment. Venom peptides from cone snails has the potential to treat myriad diseases using blockage therapies.
An alternative approach to train the immunity response is offered by researchers at the University of Illinois Chicago and California State University at Sacramento who have developed a novel strategy that redirects antibodies for other diseases existing in humans to the spike proteins of SARS-CoV-2.
Most media and public attention during the pandemic has focused upon efforts to develop an effective vaccine to prevent COVID-19, which is caused by the novel coronavirus SARS-CoV-2. Some attention has been paid to investigational therapeutics for treating infected patients,…
Darwin’s theory of evolution should be expanded to include consideration of a DNA stability “energy code” – so-called “molecular Darwinism” – to further account for the long-term survival of species’ characteristics on Earth, according to Rutgers scientists. The iconic genetic code can be viewed as an “energy code” that evolved by following the laws of thermodynamics (flow of energy), causing its evolution to culminate in a nearly singular code for all living species, according to the Rutgers co-authored study in the journal Quarterly Review of Biophysics.
Scientists at Sanford Burnham Prebys Medical Discovery Institute, University of California San Diego School of Medicine and Hopp Children’s Cancer Center Heidelberg (KiTZ) have demonstrated that personalized drug screens can be used to identify new therapeutic candidates for medulloblastoma. The approach measures the effectiveness of therapeutics using tumor cells obtained from a biopsy and can be performed in a few days—making it one of the quickest sources of information used in clinical decision-making.
A virtual symposium to highlight the impact the U.S. Department of Energy’s (DOE) National Virtual Biotechnology Laboratory (NVBL) has had utilizing the unique capabilities of the DOE to tackle the science and technology challenges associated with COVID-19, and to discuss areas in which the NVBL can have impact in the future. The event is aimed at the S&T community, media, and the general public.
A study on serotonin, a mood-regulating molecule in the brain that regulates many brain synapses, is helping to unravel the puzzle surrounding its role in autism. The activity and regulation of the serotonin transporter (SERT), protein is critically dependent on a number of other proteins that tell the protein where to locate on nerve cells and how to act. Shifts in the transporter’s activity can significantly impact the ability of serotonin to act in the brain.
The AIDS Clinical Trials Group (ACTG) has initiated the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial. ACTIV-2 includes both phase 2 and phase 3 evaluations of multiple promising investigational agents for treating early COVID-19 in a single trial.
The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies.
In recent years, genome-wide association studies (GWAS) have identified many different genetic variants associated with schizophrenia. These genetic discoveries raise the promise of developing urgently needed new treatments targeting the underlying biology and pathophysiology of schizophrenia, according to a special article in the Journal of Clinical Psychopharmacology. The journal is published in the Lippincott portfolio by Wolters Kluwer.
UNIVERSITY PARK, Pa. — The Penn State Center for Structural Oncology (CSO) is shifting some of its focus from fighting cancer to fighting COVID-19, with three projects. The CSO’s director, Deborah Kelly, Lloyd & Dottie Foehr Huck Chair in Molecular Biophysics…
The COVID-19 pandemic demands action on many fronts, from prevention to testing to treatment. Not content to focus its research efforts on just one, the laboratory of George Church in the Blavatnik Institute at Harvard Medical School and the Wyss Institute for Biologically Inspired Engineering at Harvard University is tackling the problem from seven different angles.
Researchers at the University of Illinois at Chicago recently published a study in the journal ACS Nano that details findings from computer simulations seeking to identify inhibitors, which eventually could assist chemists to develop new medicines to combat the coronavirus.
Scientists have created a mathematical model that can help explain why so many pregnancies and in vitro fertilization attempts fail. The Rutgers-led study, which may help to improve fertility, is published in the journal Proceedings of the National Academy of Sciences.